NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.387) was uploaded to the NHS England Website on Monday 23, February 2026.
The following changes have been introduced:
Epcoritamab monotherapy (EPC2)
Epcoritamab monotherapy for previously treated adult patients with relapsed/refractory follicular lymphoma who have received 2 or more lines of systemic therapy where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Carfilzomib in combination with lenalidomide and dexamethasone (CAR2)
For the treatment of previously treated multiple myeloma in patients who have had 1 prior line of systemic therapy where the following criteria have been met
Treatment criterion (#6 and 13) updated; Treatment criteria (#13) removed
Pembrolizumab (PEMB7)
Pembrolizumab for adjuvant treatment melanoma with high risk of recurrence where the following criteria have been met
Treatment criteria (#10) updated; Treatment criterion (#2 and 11) removed
Pembrolizumab (PEMB8)
Pembrolizumab in combination with pemetrexed- and platinum-based chemotherapy for the first line treatment of PD-L1 positive or negative locally advanced or metastatic non-squamous non-small cell lung cancer where all the following criteria are met:
Treatment criteria (#13) updated; Treatment criterion (#2 and 14) removed
Pembrolizumab (PEMB12)
For previously untreated metastatic or unresectable recurrent PD-L1 positive head and neck squamous cell carcinoma (HNSCC) where the following criteria have been met
Treatment criterion (#6, 7 and 10) updated; Treatment criteria (#2) removed
Pembrolizumab (PEMB14)
For the 1st line treatment of patients with either metastatic or locally advanced and inoperable colorectal cancer exhibiting microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) where the following criteria have been met
Treatment criterion (#10 and 12) updated; Treatment criterion (#2, 13 and 15) removed
Pembrolizumab (PEMB19)
Pembrolizumab monotherapy for adjuvant treatment after complete tumour resection of renal cell carcinoma in adult patients at increased risk of recurrence following nephrectomy or following nephrectomy and resection of all metastatic disease where the following criteria have been met
Treatment criterion (#8, 10 and 11) updated; Treatment criterion (#2, 11 and 13) removed
Pembrolizumab (PEMB20)
Pembrolizumab for the adjuvant treatment of newly diagnosed and completely resected stage IIB or stage IIC malignant melanoma where the following criteria have been met
Treatment criteria (#10) updated; Treatment criterion (#2 and 11) removed
Pembrolizumab (PEMB21)
Pembrolizumab in combination with chemotherapy as neoadjuvant treatment and then continued as adjuvant monotherapy after definitive surgery for patients with previously untreated locally advanced or early stage triple negative breast cancer at high risk of recurrence where the following criteria have been met
Treatment criterion (#10, 13, 15 and 17) updated; Treatment criterion (#2 and 18) removed
Pembrolizumab in combination with chemotherapy with or without bevacizumab (PEMB22)
For the treatment of persistent, recurrent or metastatic cervical cancer in patients whose tumour PD-L1 expression test results have a combined positive score (CPS) of 1 or more where the following criteria have been met
Treatment criterion (#10, 11, 15 and 16) updated; Treatment criterion (#2 and 16) removed
Pembrolizumab in combination with chemotherapy (PEMB30)
Pembrolizumab in combination with chemotherapy for neoadjuvant treatment and then continued as adjuvant monotherapy in adults with previously untreated UICC/AJCC 8th edition stage IIA or IIB or IIIA or N2 only IIIB non-small cell lung cancer AND who are candidates for potentially curative surgery where the following criteria have been met
Treatment criteria (#9) updated